A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients

Clinical Cancer Research

Volumn 16, Issue 6, 2010, Pages 1957-1967

  Sanz, David J ^a   Acedo, Alberto ^a   Infante, Mar ^a   Durán, Mercedes ^a   Pérez Cabornero, Lucía ^a   Esteban Cardeñosa, Eva ^b   Lastra, Enrique ^c   Pagani, Franco ^d   Miner, Cristina ^a   Velasco, Eladio A ^a  

^a Universidad de Valladolid y Consejo Superior de Investigaciones Científicas   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MESSENGER RNA; POLYPYRIMIDINE TRACT BINDING PROTEIN;

ARTICLE; BIOINFORMATICS; BREAST CANCER; BREAST EPITHELIUM; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; FAMILIAL CANCER; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HELA CELL; HUMAN; LYMPHOCYTE; MUTAGENESIS; MUTATION; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; RNA SPLICING;

AGE OF ONSET; ALTERNATIVE SPLICING; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; LYMPHOCYTES; MUTAGENESIS, SITE-DIRECTED; MUTATION; OVARIAN NEOPLASMS; PHENOTYPE; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 77949762254     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2564     Document Type: Article

References (48)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, et al. Identification of the Breast-Cancer Susceptibility Gene Brca2. Nature 1995;378:789-92.
3. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008;40:17-22.
4. Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007;81:873-83.
5. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006;43:295-305.
6. Cartegni L, Chew SL, Krainer AR, et al. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002;3:285-98.
7. Buratti E, Baralle M, Baralle FE. Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Res 2006;34:3494-510.
8. Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R. Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 2005;579:1900-3.
9. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007;8:749-61.
10. Baralle D, Baralle M. Splicing in action: assessing disease causing sequence changes. J Med Genet 2005;42:737-48.
11. Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 2001;27:55-8.
12. Goina E, Skoko N, Pagani F. Binding of DAZAP1 and hnRNPA1/A2 to an exonic splicing silencer in a natural BRCA1 exon 18 mutant. Mol Cell Biol 2008;28:3850-60.
13. Tournier I, Vezain M, Martins A, et al. A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects. Hum Mutat 2008;29:1412-24.
14. Infante M, Duran M, Esteban-Cardenosa E, Miner C, Velasco E. High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-Leon (central Spain). J Hum Genet 2006;51:611-7.
15. Velasco E, Infante M, Duran M, et al. Heteroduplex analysis by capillary array electrophoresis for rapid mutation detection in large multiexon genes. Nat Protoc 2007;2:237-46.
16. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. J Comput Biol 1997;4:311-23.
17. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003;31:3568-71.
18. Goren A, Ram O, Amit M, et al. Comparative analysis identifies exonic splicing regulatory sequences - the complex definition of enhancers and silencers. Mol Cell 2006;22:769-81.
19. Fairbrother WG, Yeo GW, Yeh R, et al. RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons. Nucleic Acids Res 2004;32:187-90.
20. Zhang XHF, Chasin LA. Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev 2004;18:1241-50.
21. Larkin MA, Blackshields G, Brown NP, et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007;23:2947-8.
22. Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6075-86.
23. Tesoriero AA, Wong EM, Jenkins MA, et al. Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families. Hum Mutat 2005;26:495.
24. Vega A, Campos B, Bressac-de-Paillerets B, et al. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 2001;17:520-1.
25. Thomassen M, Kruse TA, Jensen PK, Gerdes AM. A missense mutation in exon 13 in BRCA2, c.7235G>A, results in skipping of exon 13. Genet Test 2006;10:116-20.
26. Beristain E, Martinez-Bouzas C, Guerra I, et al. Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling. Breast Cancer Res Treat 2007;106:255-62.
27. Vreeswijk MP, Kraan JN, van der Klift HM, et al. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs. Hum Mutat 2009;30: 107-14.
28. Wu K, Hinson SR, Ohashi A, et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 2005; 65:417-26.
29. Hertel KJ. Combinatorial control of exon recognition. J Biol Chem 2008;283:1211-5.
30. Infante M, Duran M, Acedo A, et al. BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in Breast/Ovarian cancer families of Spanish origin. Clin Genet 2009, doi: 10.1111/j.1399-0004.2009.01272.x.
31. Vallon-Christersson J, Cayanan C, Haraldsson K, et al. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 2001;10:353-60.
32. Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006;22:719-29.
33. Farrugia DJ, Agarwal MK, Pankratz VS, et al. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 2008;68:3523-31.
34. Fackenthal JD, Cartegni L, Krainer AR, Olopade OI. BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet 2002;71:625-31.
35. Kuznetsov SG, Liu P, Sharan SK. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat Med 2008;14: 875-81.
36. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008;24:7-10.
37. Pettigrew C, Wayte N, Lovelock PK, et al. Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms. Breast Cancer Res 2005; 7:R929-39.
38. Fairbrother WG, Holste D, Burge CB, Sharp PA. Single nucleotide polymorphism-based validation of exonic splicing enhancers. Plos Biol 2004;2:1388-95.
39. Bonnet C, Krieger S, Vezain M, et al. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 2008;45:438-46.
40. Claes K, Vandesompele J, Poppe B, et al. Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5′ end of the BRCA1 gene. Oncogene 2002;21:4171-5.
41. Millevoi S, Bernat S, Telly D, et al. The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Res Treat 2009, DOI 10.1007/s10549-009-0392-3.
42. Machackova E, Foretova L, Lukesova M, et al. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer 2008;8:140.
43. Zhang L, Bacares R, Boyar S, Hudis C, Nafa K, Offit K. cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation. Mutat Res 2009;663:84-9.
44. Pagani F, Stuani C, Tzetis M, et al. New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12. Hum Mol Genet 2003;12:1111-20.
45. Milne RL, Osorio A, Cajal TR, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 2008;14:2861-9.
46. Pagani F, Buratti E, Stuani C, Bendix R, Dork T, Baralle FE. A new type of mutation causes a splicing defect in ATM. Nat Genet 2002; 30:426-9.
47. Caux-Moncoutier V, Pages-Berhouet S, Michaux D, et al. Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study. Eur J Hum Genet 2009;17:1471-80.
48. Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007;39:352-8.